Tuesday, 30 June 2015

Project assistants required_Mumbai

One of the start-ups in Mumbai requires for B. Pharm/ M. Pharm students for a minor project for the period of one month. This is not a job opportunity, but a temporary opportunity with flexible timing. 

The project is related to pharmaceutics/ drug delivery systems. Proper guidance would be provided to the students regarding the project. 

This is a home based opportunity and requires internet connection.

Internet searching; data collection, interpretation and analysis of the same. The candidate need to submit the assignment within stipulated time. 

Based on number of hours in a month.

Essential requirement:
Basic understanding of pharmaceutics. Third year/ final year B.Pharma students as well as M. Pharm students are eligible. 

Job location:
Since this is a home based opportunity, there is no restriction of the job location. However, Mumbai/ Pune or Nashik candidates are preferred. 

Please contact pharmaliterati@gmail.com with your resume. 

Pharma academic research - Indian patent applications published on 26th June 2015

Dear All,
Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at pharmaliterati@gmail.com

Indian patent applications published on 26th June 2015
Application No
Colon targeted pharmaceutical composition of Esomeprazole magnesium trihydrate and curcumin
2508/MUM/2013 A
1) Mayur Dilipkumar Kapadia
2) Dr. Subhashkumar S. Vaghani
Shree Dhanvantary Pharmacy College, Surat, Gujarat.
Multiparticulate pharmaceutical composition of Etodolac and Curcumin
2509/MUM/2013 A
1) Hinal Pankajbhai Desai
2) Dr. Subhashkumar S. Vaghani
Shree Dhanvantary Pharmacy College, Surat, Gujarat.
Topical formulations of DMARD for use in arthritis
2486/MUM/2013 A
1) Mangesh Ramesh Bhalekar
2) Ashwini Raghavendra Madgulkar
3) Sanjay Jayprakash Kshirsagar
AISSMS college of pharmacy, Kennedy Road, Near RTO, Pune-411001 Maharashtra.
Novel method for dry powder inhalation comprising antiasthamtic drugs.
1502/MUM/2013 A
1) Dr. Atmaram Pawar
2) Mr. Ashwin J Mali
3) Dr. Ravindra Purohit
4) Dr. Kakasaheb Ramoo Mahadik
Bharati Vidyapeeth Deemed University, Poona College of Pharmacy, Erandwane, Pune-411038, Maharashtra, India.
Targeted and triggered chitosan lipid core shell nanoparticles for combination chemotherapy
2469/MUM/2013 A
1) Prof. Rinti Banerjee
2) Thorat Ketan Vilas
3) Nitin Joshi
Indian Institute of Technology, Bombay.
Process for fabrication of pharmaceutical compositions using supercritical fluids
2495/MUM/2013 A
1) Patravale; Vandana Bharat
2) Fernandes; Clara Bernard
3) Swami; Megha Vishwanath
4) Velhal; Milind Krishnaji
Pharmaceutical Sciences and Technology Department,
Institute of Chemical Technology (Deemed University), Matunga (East), Mumbai.
Formulation of multiple unit tablet of Pantoprazole
1010/DEL/2013 A
1) Vipin Saini
Maharishi Markandeshwar University, Mullana, Ambala 133207 Haryana India
Formulation of multiple-unit tablet of Aceclofenac
1009/DEL/2013 A
1) Vipin Saini
Maharishi Markandeshwar University, Mullana, Ambala 133207 Haryana India
Herbal formulation of solanum khasianum, clarke and uses thereof
1007/DEL/2013 A
1) Vipin Saini
2) Sanjay Prabhakr Wate
3) Vipin Bihari Gupta
4) Randhir Singh Dahiya
5) Ravdeep Saini
6) Kishore Pandurang Busari
Maharishi Markandeshwar University, Mullana, Ambala 133207 Haryana India
Metal nanoparticles-doped antibacterial agents and methods of preparation and use
2463/DEL/2013 A
1) Nishith Verma
2) Ashutosh Sharma
3) Prateek Khare
Indian Institute of Technology, Kanpur.
An antibacterial formulation
3399/DEL/2012 A
1) Dr. Virender Singh
2) Dr Tejpal Dhewa
3) Dr. P.K. Chauhan
4) Amandeep Kaur Saini
5) Jyoti Gupta
6) Abhishek Bhardwaj
7) Rohini Sharma
8) Dr. Vinod Kumar
9) Abhishek Thakur
10) Avinash Kumar
Assistant Professor and Head, Dept. of Life Sciences,
Himachal Institute of Life Sciences Paonta Sahib (HP ).
An improved green protocol for the synthesis of 1,2-diamines via ring opening of aziridines with amines
3741/DEL/2013 A
1) Asit K. Chakraborti
2) Babita Tanwar
3) Pradeep S. Jadhavar
NIPER, Mohali
indolizine based compounds useful as potential phosphodiesterase3 (PDE3) inhibitors and a process for the preparation thereof
287/DEL/2013 A
1) Budde Mahendar
2) Saidulu Mattapally
3) Mettu Ravinder
4) Sanjay Kumar Banerjee
5) Vaidya Jayathirtha Rao
Council of Scientific & Industrial Research
Anti-diabetic composition comprising herbal extract of jatropha integerrima jacq and uses thereof
3744/DEL/2013 A
1) Prof. Surendra Kumar Sharma
2) Harneet Singh
Guru Jambheshwar University of Science and Technology, Hisar, Haryana.
Antibacterial property of green seaweed chaetomorpha sp. against helicobacter pylori
3711/DEL/2013 A
1) Dr. Subhasha Nigam
2) Dr. Rajashree Das
3) Valentina Gehlot
4) Surbhi Sinha
Amity University

India lags behind even Kenya in research

Dear All,
A recent study by Scopus database which is the world's largest abstract and citation database on scientific literature, India lags behind Kenya and Chile.

The country has only four researchers for 10,000 working people while Kenya and Chile have six and seven, respectively, according to Scopus database which is the world's largest abstract and citation database on scientific literature.

Analyzing this data, Nature magazine says Brazil, which has been growing scientifically, has 14 researchers per 10,000 working people, and China has 18. The UK and the US top the table with 79 researchers each followed by Russia with 58.

Nature Magazine, in its May 2015 report, also said: "India's publications generate fewer citations on an average than those of other science-focused nations, including Brazil and China."

It further states that relative to its size, India has very few scientists and many Indian-born researchers leave for positions abroad, while very few foreign scientists settle in India.

According to Scopus data analyzed by Nature, there are only 2 lakh fulltime researchers in India with 14% of them being women.

Principal scientific adviser to the Centre, R Chidambaram, told TOI: "I personally do not worry about numbers and ratings. But the way forward is to attract and retain talented young people. The problem is occurring at two places, one at the class 12 level, where a lot of talented people interested in pure sciences are getting into engineering and the other problem area is at the B-Tech level where a lot of good engineering researchers jump to management courses."

Dr Gajanana Birur, who had worked with Isro for two years before moving to the US and joining Nasa, says, "At one point the problem was of infrastructure. Now, as India builds up its infrastructure, there is an overall lack of environment for good research although places like Isro, IISc and IITs are doing well. This pushes people to go out."

Scopus and Nature further note that India registers far fewer applications per capita than any other top-filing nation. "It is multinationals in India that have boosted the filing rate," Nature said, indicating that research institutes are still lagging behind.

Quoting data from the World Intellectual Property Organisation, Nature says: "Domestic and foreign patents filed per 1 million population in India is at 17 compared to 4,451 in South Korea, 3,716 in Japan with even China filing 541 patents." 

Source: http://timesofindia.indiatimes.com/home/science/India-lags-behind-even-Kenya-in-research-Study/articleshow/47848357.cms?

Pharma Literati collaborates with FICCI-CCIPR

Dear All,
We are pleased to announce the collaboration with FICCI’s CCIPR, a first of its kind of course on IPR and Pharmaceutical R & D.  The course details can be accessed at http://ficcipharmacourse.ficciipcourse.in/

About Course
Federation of Indian Chambers of Commerce and Industry (FICCI) is conducting an Online Certificate Course on IPR and Pharmaceutical R&D.

To provide the platform to understand the working of pharmaceutical industry, its business models, research, regulatory aspects and its relevance with respect to intellectual property rights.

Importance of the Course
Pharmaceutical industry is a research based industry and requires scientists in huge numbers every year. The growing pharmaceutical R&D operations fuel the need for understanding IPR (Intellectual property rights) for pharmacy graduates and those in research. IPR is important in this era of globalization and competition.

The current academic syllabus of pharmacy courses do not provide adequate knowledge about the research activities in the pharmaceutical industry, the business models, intellectual property rights and their relevance in research (Pharma R & D) and business environment which is global and highly competitive.

This course is aimed to fulfill these requirements and is designed for pharmacy students and junior level scientists in the pharmaceutical industry.

As a part of this collaboration, we would publish interviews of the students of CCIPR. Also, the subscribers of the blog would be eligible for a special discount for the course.

We would keep our readers updated regarding the course announcements. 

Team Pharma Literati

KIRAN-IPR Women Scientists Scheme: Applications for 8th batch

Dear All, 
Under the KIRAN-IPR scheme initiated by Department of Science & Technology, Government of India for the women scientists, applications are invited by the Patent Facilitating Centre (PFC) of Technology Information, Forecasting and Assessment Council (TIFAC). According to the scheme women scientists would get trained in the area of Intellectual Property Rights (IPR) and their management for a period of one year. Interested and eligible candidates can apply for the same before, July 19, 2015 through online application.

Pay scale:
Rs. 20,000/- pm for MSc/ BTech/MBBS/ BPharma 
Rs. 30,000/- pm for PhD/MTech/MVSc/MPharma

Educational qualification: Candidates having Master’s Degree in Science or Bachelor’s degree in Engineering/Technology from any recognized university can apply for the scheme. 

Those who have experience of handing computerized database and have quality in subject areas like Chemistry, Drugs, Food & Pharma, Computers & Information Technology, Biotechnology, Mechanical, Production & Industrial engineering would be preferred.

Age limit: Candidates who are between 27 to 45 years of age as on June 01, 2015 can apply for the scheme.

Selection procedure: Selection of the eligible and interested candidates would be done through conducting an all India examination and interview.

How to apply: Candidates who are willing to apply for the scheme can submit their application in a prescribed format through online mode by visiting the official website before July 19, 2015.


5 drug categories having the biggest impact on pharma spending in the future

Dear All,

The transformations taking place throughout all healthcare sectors will have repercussions for the pharmaceutical industry. How will they affect industry prospects, and what are the implications for drug manufacturers be affected?

According to Matthew Hudes, US Managing Principal for Deloitte’s Biopharma practice, the pharmaceutical industry is poised to enter an “inflection point” in which it may produce more medicines that have a dramatic impact on disease than ever before.

This is being spurred, Hudes said, by the industry’s need to replenish a tidal wave of patent expirations and by a new-found willingness to embrace “open innovation,” the practice of working with other organizations, even competitors, in obtaining the medical and scientific expertise needed to develop better therapies. 

Deloitte recently issued a report showing that drugs sourced via open innovation are 3 times more likely to achieve late-phase clinical success versus those cultivated under an in-house, closed-model approach.

“The new products hitting the market foreshadow a new era in which biopharma plays a more significant role in healthcare,” said Hudes. “Among other areas, will be a sizable wave of activity in infectious disease treatments, immunotherapies and the treatment of extreme clinical phenotypes caused by rare genetic variations, such as PCSK9, in cholesterol.  These are some of the conditions in which biopharma can make a substantial impact on outcomes and costs.”

With that context, here are 5 drug categories that may command the most impact on pharma spending in the near future:

1. Hepatitis C

2. Oncology

3. PCSK9 inhibitors (proprotein convertase subtilisin/kexin 9) enzyme inhibitors

4.  Cystic fibrosis

5. Heart failure

Source: http://formularyjournal.modernmedicine.com/formulary-journal/news/5-drug-categories-having-biggest-impact-pharma-spending

Young professionals program_NITI Aayog

National Institution for Transforming Indian (NITI) has been constituted on 1st January, 2015.

NITI Aayog seeks to engage 20 (Twenty) Young Professionals with an aptitude for Public Policy and Development under the Young Professionals programme.

The Young Professionals Programme (YPP) seeks to provide a unique opportunity for persons below the age of 32 years of exposure to Public Policy and Development.

It seeks to engage persons with a passion for development and the potential to become future leaders in their respective fields.

Under this programme, highly qualified, motivated individuals will work in the NITI Aayog in areas that are relevant to development policy and provide high quality professional inputs in Economics, Finance, Education, Public Health, Social Sciences, Engineering, Urban Planning and Infrastructure amongst others.

This highly selective programme requires candidates to demonstrate proven academic, credentials, professional achievement and leadership qualities.

The YPP seeks to provide an opportunity to gain experience in NITI Aayog of policies and programmes of the Government of India.

1. Job Description and Responsibilities:
The Young Professionals will have exposure to Public Policy, Planning and Development.
They will be required to provide high quality inputs in disciplines like Economics or Finance or Education or Public Health or Social Sciences or Engineering or Urban Planning and Infrastructure etc.
This would require demonstration of proven academic credentials, professional achievements and leadership qualities on the part of the aspirants.

2. Qualifications and Experience:
Essential: Persons having Masters Degree in relevant subiect or technical qualifications like B.Tech, MBA or equivalent in relevant field/subject.

Desirable: Persons with M.Phil or additional qualifications, research experience, published papers and post qualification experience in the relevant field would be preferred.

Work Experience: Minimum of One Year of Work Experience relevant to the job description. The broad work experience to be based on the functional areas assigned to NITI Aayog.

Preference will be given to persons with good work experience in the relevant field as evident by published work! policy papers/appraisal/monitoring of projects & schemes etc.

Other Attributes: Candidate should have good knowledge on working on computer and ability to demonstrate ICT applications. The candidate should also possess good inter-personal and strong communication skills.

3. Duration: Initially for a period of 2 vears. (can be extended unto 5 vears – one vear at a time, on the recommendations of Performance Appraisal Board! In case a person leaves before completion of one year, he/she will not get any work certificate.

4. Age Limit: Below 32 years as on 1st July of the year of engagement.

5. Fee and Conveyance:
(a) Rs.40,000 [with ceiling of Rs. 70,000 per month] per month inclusive of Transport Allowance.
(b) There shall be annual increase of Rs. 5000.

6. How to apply: Interested candidates may send their bio-data in the enclosed format (Annexure-I) by post or email so as to reach the NITI Aayog by the close of office (5.30 p.m.) within 6 weeks from the publication of this advertisement in the newspaper (at the following address:

The Section Officer
(Admn.I) Room No. 416
NITI Aayog,
Sansad Marg, New Delhi- 110001
e-mail address: recruitment-niti@gov.in

Source: http://niti.gov.in/mgov_file/NITI_YPs.pdf

Monday, 29 June 2015

Meet our bloggers_Kabin Maleku

Dear All,
We had posted about bloggers joining our team.

We are pleased to welcome our third blogger in the series, Mr. Kabin Maleku from the beautiful country of Nepal.   He has done her M. Pharma from BITS Pilani and B. Pharma from NET pharmacy college, Raichur. 
We welcome Kabin to our team and wish a luck in the endeavor. 

To join as a blogger with Pharma Literati team, send your CV to pharmaliterati@gmail.com

Team Pharma Literati.

Thursday, 25 June 2015

CIMS available on Mobile application

Dear All,
The medical fraternity has been using CIMS since long. The database used for critical prescription information, medical news and articles is now available as mobile application. 

The Free CIMS app delivers critical prescribing information, medical news and CME articles as well as clinical calculators essential to physicians’ daily practice needs. With CIMS available across multiple platforms and devices, you can now easily and conveniently find the most up-to-date and relevant drug information you need anytime, anywhere.

Wednesday, 24 June 2015

It's raining resignations at Cipla

Kamil Hamied has quit Cipla, surprising those who had expected him to take a leadership role at India's third-largest drug company. A few months ago, Cipla founder YK Hamied had referred to nephew Kamil (33) and the latter's sister Samina Vaziralli (38) as family members who would carry on the family tradition.
A Cipla spokesperson said the younger Hamied was leaving to pursue his own interests and sought to downplay the suggestion that there might have been disaffection on his part, making the point that he had backed the move to bring in professional managers to run the drug maker. Cipla has been going through a spell of turmoil of late, with several changes at the top.

Hamied was chief strategy officer and managed European operations before Frank Peters was hired to take charge of the region. There has been talk about Hamied having an uncomfortable working relationship with Subhanu Saxena, who was appointed chief executive officer in 2012.
To be sure, many family run Indian firms are increasingly professionalising by hiring CEOs and other top managers with global experience and proven ability. Hamid's exit also raises questions about his induction on board, where he was expected to get an elevated role that would have taken him a step closer to the top.
Cipla has seen a top management reshuffle coupled with uncertainty over the business since the team led by Saxena took charge. Saxena is considered one of the highest paid CEOs in India, with a remuneration of Rs 21 crore according to 2013-14 annual report, and was hired with the intention of globalising the business and going into markets where Cipla had not ventured before. However, the ride has been anything but smooth and Saxena has had to face investors' queries over consistently low growth amid the changes at the top.

The resignation of Sameer Goel as India head within a year of joining has added to the speculation about the company's growth path. In April, CLSA downgraded Cipla over lack of clarity on the launch of the company's much-awaited dry powder inhaler (DPI) launch. Saxena cancelled an interview request from ET because of his travel schedule.

Source: http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/successor-in-waiting-kamil-hamied-leaves-cipla-to-pursue-his-own-interests/articleshow/47794039.cms

Tuesday, 23 June 2015

Govt releases report on enabling growth of pharm sector

Dear All,
The Union Minister of Chemicals & Fertilizers, Ananth Kumar has released Task Force report on enabling the Private Sector to lead the growth of pharmaceutical sector

Speaking at the release ceremony in New Delhi the Minister said that the Government wants to encourage a robust Pharmaceutical Industry in the country that is upgraded, standardized, innovative, globally competitive and can produce formulations at affordable costs. He said in this regard, setting up of the Task Force was one of the major initiative of the Government.The Task Force has given recommendations towards concerns and constraints facing the sector and suggested measures that would augment domestic production. Ananth Kumar said that the Government is very keen on early implementation of the recommendations of the Task Force and it would come out with an action taken report on these recommendations in 100 days.

Speaking on the occasion, Minister of State for Chemicals and Fertilizers Hansraj Ahir said that the Government is promoting 'Make in India' as well as 'Skill India' Mantras of the Prime Minister. He said that the Pharmaceutical sector has to compete globally and for this, better standards and improved facilities are required. Ahir said that the Government is willing and keen to facilitate the growth of Pharmaceutical sector in the country.

The Secretary, Department of Pharmaceuticals, Dr. V.K. Subburaj said that the exports of pharmaceuticals by Indian Companies is a success story. However, regulations in the sector are weak in the country and that is affecting the further growth. He said that the Department has taken several steps to bring awareness in the industry for improving the standards. Dr. Subburaj further said that Pharmaceutical Sector is also suffering due to multiple decision making authorities. 

The Task Force has recommended a Joint Committee which can take care of their problems. To provide thrust to the sector, a Task Force on Enabling the Private Sector to lead the growth of Pharmaceutical Sector was set up by the Department of Pharmaceuticals. The Task Force was headed by Secretary, Department of Pharmaceuticals and consisted of representatives from Planning Commission, Department of Industrial Policy and Promotion, Department of Science and Technology, Department of Biotechnology and various Industry Associations including IPA, IDMA, BDMA, OPPI, AIMED, CIIO, FICCI, ASSOCHAM, FOPE etc. 

The Task Force has recommended measures to enhance regulatory support; suggested strengthening of infrastructural support; and recommended fiscal and financial support to the sector. In addition, the Task Force has also recommended measures for promoting skill development aligned to the need of the industry, strengthening the R&D capability of the sector, pricing strategy for the sector. 

See more at: http://www.smetimes.in/smetimes/news/top-stories/2015/Jun/23/govt-releases-report-on-enabling-growth-of-pharm-sector632426.html#sthash.Sj5HQmmu.dpuf